Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL)

Trial Profile

Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (RIVe-CLL)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Idelalisib (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms RIVe-CLL
  • Most Recent Events

    • 22 Jan 2019 Planned initiation date changed from 31 Jan 2019 to 30 Mar 2019.
    • 13 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 31 Jan 2019.
    • 15 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top